Al­ways busy, Gary Glick re­cruits Or­biMed in a mas­sive $218M Se­ries A for enig­mat­ic da­ta sci­ence biotech

Gary Glick is back at it again, found­ing yet an­oth­er biotech com­pa­ny. And by the sheer size of its first raise, this may be the biggest one yet.

Glick has as­sem­bled what he calls an all-star ros­ter and re­cruit­ed one of the biggest health­care in­vestors in Or­biMed to put to­geth­er a mas­sive $218 mil­lion Se­ries A for his newest ven­ture, Odyssey Ther­a­peu­tics. The launch, an­nounced Tues­day morn­ing and co-led by SR One Cap­i­tal Man­age­ment, comes not three months af­ter Glick sold First Wave Bio to Azur­Rx for $229 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER